Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery-Reference-Cited by-同舟云学术

Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery

Published:2020-11-11 Issue:2 Volume:28 Page:143-155
ISSN:1868-6974
Container-title:Journal of Hepato-Biliary-Pancreatic Sciences
language:en
Short-container-title:J Hepatobiliary Pancreat Sci

Author:

Inoue Yosuke¹^ORCID,Saiura Akio¹²,Oba Atsushi¹,Ono Yoshihiro¹,Mise Yoshihiro¹²,Ito Hiromichi¹,Sasaki Takashi³,Ozaka Masato³,Sasahira Naoki³,Takahashi Yu¹^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Surgery Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Hepatobiliary Pancreatic Surgery Juntendo University Hospital Tokyo Japan

3. Department of Gastroenterological medicine Cancer Institute HospitalJapanese Foundation for Cancer Research Tokyo Japan

Publisher

Wiley

Subject

Hepatology,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jhbp.844

Reference41 articles.

1. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

2. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

3. Cancer statistics, 2019

4. Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

5. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer;The American Surgeon™;2024-08-24

2. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic Cancer Abutting Major Arteries;The American Surgeon™;2024-08-22

3. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer;The American Surgeon™;2024-08-07

4. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma;Annals of Surgical Oncology;2024-06-26

5. Neoadjuvant therapy with intensity‐modulated radiotherapy combined with S‐1 for borderline‐resectable pancreatic cancer;Asia-Pacific Journal of Clinical Oncology;2024-05-21